Plasma pentosidine: a potential biomarker in the management of multiple sclerosis

Autor: Latif Kazim, Frederick Munschauer, Kailash C. Chadha, Zohara Sternberg, Ralph H.B. Benedict, Cassandra Hennies, Daniel Sternberg, Christopher Leung, Gaia Bistulfi, Bianca Weinstock-Guttman
Rok vydání: 2010
Předmět:
Oncology
Adult
Male
medicine.medical_specialty
Time Factors
New York
Inflammation
Arginine
Severity of Illness Index
chemistry.chemical_compound
Disability Evaluation
Degenerative disease
Multiple Sclerosis
Relapsing-Remitting
Downregulation and upregulation
Glycation
Predictive Value of Tests
Recurrence
Internal medicine
medicine
Humans
Pentosidine
Chromatography
High Pressure Liquid
Analysis of Variance
business.industry
Multiple sclerosis
Lysine
Middle Aged
Multiple Sclerosis
Chronic Progressive
medicine.disease
Management of multiple sclerosis
Up-Regulation
Endocrinology
Cross-Sectional Studies
Spectrometry
Fluorescence
Treatment Outcome
Neurology
chemistry
Potential biomarkers
Case-Control Studies
Linear Models
Female
Neurology (clinical)
medicine.symptom
Inflammation Mediators
business
Biomarkers
Zdroj: Multiple sclerosis (Houndmills, Basingstoke, England). 17(2)
ISSN: 1477-0970
Popis: Background: The chronic inflammation associated with multiple sclerosis (MS) may lead to the upregulation of pentosidine. Objectives: This cross-sectional study compares plasma pentosidine levels among healthy controls (HCs) and patients with MS at different disease stages. The study also determines pentosidine's usefulness as a biomarker of MS disease activity and/or severity via its correlation with a number of indicators of MS disease. Methods: Pentosidine levels were analyzed in 98 MS patients and 43 HCs using reverse-phase high-pressure liquid chromatography with fluorescence detection. Results: Plasma pentosidine levels were significantly higher in MS patients when compared with HCs ( p = 0.02). Patients on disease-modifying therapies (DMTs) had lower plasma pentosidine levels when compared with DMT-naïve patients ( p = 0.01). Pentosidine plasma levels correlated with indicators of MS disease severity, including Extended Disability Status Scale ( p = 0.03), MS Severity Scale ( p = 0.01), and MS Functional Composite ( p = 0.03). No correlation between pentosidine levels and age, rate of clinical relapse, and disease duration was observed. Conclusions: Our results suggest that pentosidine could be a novel, inflammatory biomarker in MS clinical practice. Longitudinal studies are warranted to determine any causal relationship between changes in plasma pentosidine levels and MS disease pathology. These studies may pave the way for use of advanced glycation end product (AGE) inhibitors and AGE-breaking agents as new therapeutic modalities in MS.
Databáze: OpenAIRE
Externí odkaz: